NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ('NRx Pharmaceuticals”, the 'Company”), a clinical-stage biopharmaceutical company, ...
Total sales for the fourth quarter were $112.1 million, down 6.0% from $119.2 million for the fourth quarter of fiscal 2024.
Full year 2025 HighlightsAchieved full-year production guidance with 34,098 gold-equivalent ounces ("GEOs") produced in ...
Yiren Digital Ltd. (NYSE: YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results